drugset / Trial / NCT01814332

Analyzing Female Trauma Exposed Responses to a Medication

NCT01814332

Phase 2 Completed 128 enrolled VA Office of Research and Development
RandomizedParallel-groupTriple-blindTreatment

Summary

This purpose of this study is to look at the safety of the experimental drug GSK561679 as well as its effects on PTSD symptoms, thinking and memory, startle reaction, stress hormones, and mental health symptoms in comparison to placebo (an inactive substance).

Timeline

Start
2010-01-01
Primary completion
2014-06-30
Completion
2014-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject VERUCERFONT Small molecule 350 mg Oral